CTOs on the Move

Reset Therapeutics

www.resettherapeutics.com

 
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body`s network of internal molecular clocks. The circadian system synchronizes behavioral and physiological processes, including sleep, metabolism, feeding, blood pressure and hormone secretion with the environmental cycles of light, activity and nutrient status. Disruption of normal circadian rhythms is associated with many diseases, including central nervous system, cardiovascular and metabolic disorders, immune system dysfunction and cancer. Novel therapies that reset the body’s biological clocks have the potential to benefit very large and diverse patient populations
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Reset Therapeutics raised $29.73M on 02/19/2016

Similar Companies

Global CINRG

Global CINRG is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BTL Industries

Founded in 1993, BTL has grown to become one of the world’s major manufacturers of medical equipment. BTLs major segments include physical therapy, cardiology and medical aesthetics.

PharmaLeaders

PharmaLeaders is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.

U.S. Urology Partners

U.S. Urology Partners is a physician-led management services organization that provides business support services to our network of urology practices .